ACTR2 and diffuse large B-cell lymphoma: More importantly, the progression of DLBCL could be retarded through the knockdown of ACTR2 to block the Wnt signaling, implicating ACTR2 as a promising biomarker in the diagnosis and treatments of DLBCL.